Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Stetter Mark reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Mark Stetter reported receiving a grant of 317.6216 phantom stock units tied to Zoetis common stock, based on a value of $78.71 per unit. These units reflect the deferral of his director cash retainer into the Zoetis stock fund and bring his total phantom stock unit balance to 534.0883. Each phantom stock unit is economically equivalent to one Zoetis common share but will be settled in cash after he separates from service, so this filing reflects non-employee director compensation rather than an open-market stock purchase or sale.
Zoetis Inc. Executive Vice President Abhay U. Nayak filed an initial ownership report as he again became a Section 16 officer on June 15, 2026. The filing shows no directly held shares of Zoetis common stock but discloses multiple equity-based awards and deferred units tied to the stock price.
He holds phantom stock units under the Zoetis Supplemental Savings Plan linked to 1,508.7729 underlying shares of common stock, which will be settled in cash after separation from service. The report also lists stock options granted under Zoetis equity plans, including 8,106 options with a stated exercise price of $0.00 per share and additional option grants over several years with exercise prices such as $162.07, $196.14, $156.64 and $129.13 per share.
In addition, Nayak is reported to hold restricted stock units (RSUs) that each represent a contingent right to receive one share of Zoetis common stock. These RSUs, including blocks such as 1,902.1798 and 1,122.8284 underlying shares, generally vest in one-third installments on the first, second and third anniversaries of their respective grant dates, subject to continued service and certain earlier-vesting provisions.
Zoetis Inc. director Michael B. McCallister reported a bona fide gift of 1,209 shares of Zoetis common stock. The shares were transferred from his direct holdings to a trust where he serves as trustee, consolidating ownership within a family trust structure.
Following the transaction, McCallister reports no directly held Zoetis shares and 31,893 shares held indirectly by the Michael and Charlene McCallister Family Trust DTD 11/14/2014. The filing shows no option exercises or sales; the activity reflects estate and account administration rather than market trading.
Zoetis Inc. director Mark Stetter acquired common stock through vesting of restricted stock units (RSUs) on May 21, 2026. He exercised RSUs to receive 1,572 shares of Zoetis common stock as equity compensation, with no open‑market sale reported in this filing.
The RSUs convert on a one‑for‑one basis into common shares upon vesting, consistent with grants under the Zoetis Amended and Restated 2013 Equity and Incentive Plan. After this event, he holds 1,572 common shares directly and retains additional RSU-based rights to Zoetis stock.
Zoetis Inc. reported results of its 2026 Annual Meeting of Shareholders and a Board change. Effective May 20, 2026, director Louise M. Parent retired from the Board in line with the company’s director retirement policy.
Shareholders representing 379,034,516 shares, or 90.13% of voting power as of the March 27, 2026 record date, were present, establishing a quorum. All twelve director nominees were elected for one-year terms, and shareholders approved, on a non-binding basis, the executive compensation program and chose to hold this advisory vote every year.
Shareholders also ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. A shareholder proposal to permit shareholder action by written consent did not receive sufficient support and was not approved.
Zoetis Inc. director Louise M. Parent acquired common stock through equity award settlements rather than market trades. On May 20, 2026, she received 10,186 shares upon vesting and settlement of deferred stock units and 1,944 shares upon vesting and settlement of restricted stock units, both in connection with her retirement from the Zoetis Board of Directors. These transactions reflect the conversion of fully vested DSUs and RSUs, with no open-market buying or selling reported and no remaining derivative units shown after settlement.
Zoetis Inc. announced that its Board of Directors declared a cash dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on September 1, 2026 to shareholders of record as of the close of business on July 20, 2026. This reflects ongoing cash returns to common stockholders through regular dividend payments.
Zoetis Inc. director Frank A. D'Amelio bought shares of the company in the open market. He purchased 6,650 shares of Zoetis common stock at a price of $75.39 per share in a single transaction. Following this purchase, he directly owns 21,458 shares of Zoetis common stock.
Zoetis Inc. director Paul Bisaro reported an open-market buy of Common Stock. On May 13, 2026, he purchased 2,000 shares at $75.875 per share in a single transaction. Following this purchase, his direct holdings increased to 27,862 shares of Zoetis common stock.
Zoetis Inc. director Michael B. McCallister reported an open-market purchase of 3,000 shares of Zoetis common stock. The shares were bought indirectly through a family trust at a weighted average price of $77.7578 per share, with individual trade prices ranging from $77.72 to $77.80.
After this purchase, one trust associated with McCallister holds 24,524 Zoetis shares indirectly, while separate records show 1,209 shares held directly and additional shares held through another trust for his spouse and family.